@prefix dcterms: . @prefix ns1: . @prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "bortezomib for injection is a proteasome inhibitor indicated for treatment of patients with multiple myeloma 1 1 treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy 1 2 bortezomib for injection is indicated for the treatment of patients with multiple myeloma bortezomib for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation schema:TreatmentIndication . bl:category bl:Drug . } sub:provenance { sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "dtVLUtonn7+7acexedTXXSLtoYsUK9Jz/sFet/bztf+9YYOX63NGGYnwPr+Db/0pfoZh2UReGCDeUsXtjbZRbSgM29R7slawzbKMspCnYmw+mcRArPgD9Aaa2mgxGbS+RUBXx/Mn2cb4ZfReo9Z2DkGGjVlQiF3q/RFgpyDoFc4="; npx:hasSignatureTarget this: . this: dcterms:created "2021-06-27T20:11:57.454+02:00"^^xsd:dateTime; dcterms:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }